Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT01285752 Completed - Clinical trials for Rheumatoid Arthritis

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

NCT ID: NCT01285336 Completed - Clinical trials for Rheumatoid Arthritis

The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis

Start date: August 2010
Phase: N/A
Study type: Interventional

This study is valuable for the understanding the role of DNA repair system plays in the progression of rheumatoid arthritis and for the development of new therapeutic modality in the future.

NCT ID: NCT01284569 Completed - Clinical trials for Rheumatoid Arthritis

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

Start date: March 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the ALX-0061, a Nanobody targeting the receptor for interleukin 6 (IL6R), is safe and effective after single or multiple administrations to patients with rheumatoid arthritis (RA). Patients will receive different single or multiple doses of either placebo or ALX-0061.

NCT ID: NCT01284283 Completed - Clinical trials for Rheumatoid Arthritis

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

STAR 2 PAS
Start date: November 2009
Phase: N/A
Study type: Interventional

This post-approval study is being conducted to examine the performance of the STAR Ankle under actual conditions of use.

NCT ID: NCT01283399 Completed - Clinical trials for Rheumatoid Arthritis

An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

Start date: August 2010
Phase: N/A
Study type: Observational

This observational study will assess the efficacy and safety of combination of rituximab (MabThera) and methotrexate in participants with active refractory rheumatoid arthritis (RA) who have failed to respond to a single course of anti-tumor necrosis factor (TNF) therapy in routine clinical practice. Data will be collected from participants for 12 months after the first dose of rituximab or a minimum of 6 months following a rituximab re-treatment course.

NCT ID: NCT01282372 Completed - Clinical trials for Rheumatoid Arthritis

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Start date: March 2011
Phase: N/A
Study type: Observational

Treatment with tumor necrosis factor (TNF) inhibitors, especially adalimumab, demonstrated an improvement in work productivity in participants with rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Limited data was available for the effect of adalimumab treatment on sleep in all three diseases (RA, PsA, and AS) and no data was available for the effect of adalimumab treatment on work productivity in PsA. This long term Health-Related Quality of Life (HRQL) observational study was conducted to evaluate the effect of treatment with adalimumab on work productivity and sleep disturbance in Greek participants with moderate to severe rheumatic diseases (RA, PsA, and AS).

NCT ID: NCT01282255 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo in subjects with active Rheumatoid Arthritis (RA).

NCT ID: NCT01274182 Completed - Clinical trials for Rheumatoid Arthritis

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.

NCT ID: NCT01273519 Completed - Clinical trials for Rheumatoid Arthritis

Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without comorbidities, which do not constitute a contraindication for adalimumab as stated in the released summary of product characteristics. Therefore it shall be evaluated if pain medication which is used in these participants is changed, reduced or stopped due to adalimumab treatment.

NCT ID: NCT01272908 Completed - Clinical trials for Rheumatoid Arthritis

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

Start date: n/a
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.